WO2021007245A1 - Novel methods - Google Patents

Novel methods Download PDF

Info

Publication number
WO2021007245A1
WO2021007245A1 PCT/US2020/041063 US2020041063W WO2021007245A1 WO 2021007245 A1 WO2021007245 A1 WO 2021007245A1 US 2020041063 W US2020041063 W US 2020041063W WO 2021007245 A1 WO2021007245 A1 WO 2021007245A1
Authority
WO
WIPO (PCT)
Prior art keywords
lumateperone
treatment
bipolar
disorder
foregoing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/041063
Other languages
French (fr)
Inventor
Sharon Mates
Robert Davis
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74066254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2021007245(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020227003969A priority Critical patent/KR20220029744A/en
Priority to EP20837066.8A priority patent/EP3993798A4/en
Priority to AU2020311894A priority patent/AU2020311894B2/en
Priority to CA3141223A priority patent/CA3141223A1/en
Priority to JP2022500683A priority patent/JP7673040B2/en
Priority to CN202080049820.3A priority patent/CN114072150A/en
Priority to BR112022000231A priority patent/BR112022000231A2/en
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Priority to EP22191949.1A priority patent/EP4134101A1/en
Priority to MX2022000143A priority patent/MX2022000143A/en
Publication of WO2021007245A1 publication Critical patent/WO2021007245A1/en
Priority to MX2025005489A priority patent/MX2025005489A/en
Priority to IL289589A priority patent/IL289589A/en
Anticipated expiration legal-status Critical
Priority to JP2025071306A priority patent/JP2025121928A/en
Priority to AU2025234205A priority patent/AU2025234205A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the present disclosure relates to use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, for the treatment of Bipolar II Disorder.
  • Substituted heterocycle fused gamma-carbolines such as lumateperone are known to be 5-HT 2A or 5-HT2A/D2 receptor ligands, which are useful in treating central nervous system disorders. These compounds antagonize the serotonin-2A (5-HT2A) receptor, and/or modulate dopamine receptor signaling at the level of key intra-cellular phosphoproteins. Such compounds are principally known to be useful for the treatment of positive and negative symptoms of schizophrenia. At dopamine D2 receptors, these compounds have dual properties and act as both post-synaptic antagonists and pre-synaptic partial agonists.
  • the compounds also stimulate serotonin reuptake inhibition, providing antidepressant activity for the treatment of schizoaffective disorder, co- morbid depression, and/or as a stand-alone treatment for major depressive disorder.
  • the 5-HT 2A or 5-HT2A/D2 receptor ligands as described are also useful for the treatment of bipolar disorder and other psychiatric and neurodegenerative disorders, particularly behavioral disturbances associated with dementia, autism and other CNS diseases. These features may be able to improve the quality of life of patients with schizophrenia and enhance social function to allow them to more fully integrate into their families and their workplace. These compounds display differential dose-dependent effects, selectively targeting the 5-HT 2A receptor at low doses, while progressively interacting with the D2 receptor at higher doses. As a result, at lower doses, they are useful in treating sleep, aggression and agitation. At a high-dose, they can treat acute exacerbated and residual schizophrenia, bipolar disorders, and mood disorders.
  • Lumateperone which is 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-lH- pyrido[3',4': 4,5]pyrrolo[l,2,3-de]quinoxalin-8(7H)-yl)-l-(4-fluorophenyl)-l-butanone, having the formula:
  • PCT/US08/03340 and U.S. Pat. No. 7,081,455 also disclose methods of making substituted heterocycle fused gamma- carbolines and uses of these gamma-carbolines as serotonin agonists and antagonists useful for the control and prevention of central nervous system disorders such as addictive behavior and sleep disorders.
  • WO 2011/133224 and U.S. 8,993,572 each incorporated herein by reference, disclose prodrugs/metabolites of substituted heterocycle fused gamma-carbolines for improved formulation, e.g., extended/controlled release formulation.
  • This application discloses that heterocycle fused gamma-carboline N-substituted with a 4-fluorophenyl(4-hydroxy)butyl moiety are shown to have high selectivity for the serotonin transporter (SERT) relative to the
  • WO 2009/145900 and U.S. 8,598,119 teaches that selected substituted heterocycle fused gamma-carboline compounds have nanomolar affinity for the serotonin reuptake transporter (SERT) and so are selective serotonin reuptake inhibitors.
  • SERT serotonin reuptake transporter
  • bipolar disorder also known as manic-depressive illness
  • manic-depressive illness is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
  • bipolar disorder There are four basic types of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely“up,” elated, and energized behavior (known as manic episodes) to very sad,“down,” or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
  • Bipolar I Disorder- defined by manic episodes that last at least 7 days, or by manic
  • depressive episodes occur as well, typically lasting at least 2 weeks.
  • Episodes of depression with mixed features having depression and manic symptoms at the same time are also possible.
  • Bipolar II Disorder defined by a pattern of depressive episodes and hypomanic episodes, but not the full-blown manic episodes described above.
  • Cyclothymic Disorder also called cyclothymia
  • hypomanic symptoms as well numerous periods of depressive symptoms lasting for at least 2 years (1 year in children and adolescents). However, the symptoms do not meet the diagnostic requirements for a hypomanic episode and a depressive episode.
  • bipolar disorder remains unclear, and the disorder remains resistant to treatment.
  • Pharmaceutical treatments include mood stabilizing drugs, such as lithium or anticonvulsants (e.g., carbamazepine, lamotrigine, and valproate).
  • mood stabilizing drugs such as lithium or anticonvulsants (e.g., carbamazepine, lamotrigine, and valproate).
  • Conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are not only less effective for treating bipolar depression than for major depressive disorder, but they may do harm, by triggering manic episodes and rapid cycling.
  • SSRIs selective serotonin reuptake inhibitors
  • Antipsychotic medications are generally effective for short-term treatment of bipolar manic episodes in Bipolar I Disorder, but they are generally ineffective in treating Bipolar II Disorder and in maintenance treatment during depressive episodes. Moreover, many
  • antipsychotic medications exhibit significant side effects, such as extrapy rami dal symptoms including acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome.
  • Bipolar II Disorder is often misdiagnosed as either Major Depressive Disorder or Bipolar I Disorder, and improperly treated as a result.
  • Bipolar II Disorder is often misdiagnosed as either Major Depressive Disorder or Bipolar I Disorder, and improperly treated as a result.
  • lumateperone is useful to treat Bipolar II Disorder.
  • Clinical results suggest that lumateperone is at least as effective in this indication as existing antipsychotic agents in treating bipolar disorders, with particularly unexpected efficacy in Bipolar II Disorder, which is often resistant to treatment with antipsychotic agents.
  • lumateperone exhibits a favorable safety profile.
  • the clinical trials demonstrate that, unlike many other antipsychotic agents, lumateperone does not increase akathisia, restlessness, or other movement disorders, it does not increase suicidal ideation, and it does not have significant metabolic side effects.
  • the present disclosure provides a method for treating Bipolar II Disorder in a patient in need thereof, comprising administering a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form, to a patient in need thereof.
  • MDRS Montgomery-Asberg Depression Rating Scale
  • CGI-BP-S Clinical Global Impression Scale for Bipolar for Severity of Illness
  • the patients did not exhibit emergence of mania as measured by the Young Mania Rating Scale (YMRS) and a specific clinical global impression of severity for mania, meaning that the drug was effective in preventing the emergence of mania or hypomania, and did not trigger manic episodes or cause rapid cycling that is often linked to SSRIs in treatment of bipolar disorders.
  • YMRS Young Mania Rating Scale
  • Lumateperone demonstrated a favorable safety profile in this trial, comparable to placebo. Unlike quetiapine, lumateperone did not appear to have any noticeable metabolic effects, such as such as hyperglycemia, dyslipidemia, or weight gain. There were no adverse event reports of suicidal ideation, no suicides, and no discontinuations due to suicidal thoughts. Equally important, there were also no adverse event reports of extrapy rami dal symptoms, such as akathisia, restlessness, or other motor side effects.
  • the present disclosure provides a method (Method 1) for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form.
  • Method 1 for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form.
  • Method 1 wherein the lumateperone is in the form of the tosylate salt (e.g., an acid addition salt of toluenesulfonic acid, such as a mono-tosylate salt or bis-tosylate salt), optionally wherein the salt is a solid crystalline salt, such as those disclosed in US 2011/112105 and/or US 2020/0157100, the contents of each of which are incorporated by reference herein in their entireties.
  • the tosylate salt e.g., an acid addition salt of toluenesulfonic acid, such as a mono-tosylate salt or bis-tosylate salt
  • the salt is a solid crystalline salt, such as those disclosed in US 2011/112105 and/or US 2020/0157100, the contents of each of which are incorporated by reference herein in their entireties.
  • the lumateperone is in deuterated form, e.g., wherein the deuterium: protium ratio for a specified carbon-bound hydrogen atom is significantly higher, e.g., at least 2x, for example at least lOx higher, than the natural isotope ratios.
  • D represents a hydrogen position with substantially greater than natural deuterium incorporation (i.e., substantially greater than 0.0156%), e.g., greater than 60%, or greater than 70%, or greater than 80%, or greater than 90% or greater than 95%, or greater than 96%, or greater than 97%, or greater than 98%, or greater than 99%, in free or pharmaceutically acceptable salt form, e.g. tosylate salt form.
  • any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 6 to 60 mg of free base, e.g., equivalent to 20-50 mg of free base.
  • any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 25-30 mg of free base.
  • any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 40-45mg of free base.
  • the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 42 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
  • the method comprises once daily administration of a tablet or capsule comprising about 60 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
  • any foregoing method wherein the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 28 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
  • any foregoing method wherein the method comprises once daily administration of a tablet or capsule comprising about 40 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
  • the method comprises once daily administration of a unit dosage for subcutaneous or transmucosal administration, e.g., a sublingual or buccal orally disintegrating tablet or film, comprising lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, in an amount equivalent to 10-60 mg of free base, and a pharmaceutically acceptable diluent or carrier.
  • any foregoing method wherein the method comprises administration of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in a long acting injectable form.
  • Any foregoing method wherein the condition to be treated is depression in Bipolar II Disorder, or a depressive episode associated with Bipolar II Disorder (e.g., a major depressive episode).
  • any foregoing method wherein the condition to be treated includes mixed affective episodes in Bipolar II Disorder.
  • any foregoing method wherein the condition to be treated includes hypomanic episodes.
  • MADRS Montgomery-Asberg Depression Rating Scale
  • HAM-D Hamilton Depression Rating Scale
  • BDI Beck Depression Inventory
  • Zung Self-Rating Depression Scale the Wechsler Depression Rating Scale
  • Raskin Depression Rating Scale the Inventory of Depressive Symptomatology (IDS)
  • IDS Inventory of Depressive Symptomatology
  • QIDS Quick Inventory of Depressive Symptomatology
  • any foregoing method wherein, during the course of treatment, the patient shows improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score (e.g., improvement within 8 days or less after initiation of treatment).
  • MADRS Montgomery-Asberg Depression Rating Scale
  • CGI-BP-S Clinical Global Impression Scale for Bipolar for Severity of Illness
  • CGI-BP- Depression-S Clinical Global Impression Scale for Bipolar Depression for Severity of Illness
  • CGI-S Clinical Global Impression - Severity
  • CGI-I Clinical Global Impression- Improvement
  • any foregoing method wherein the treatment does not induce extrapy rami dal symptoms e.g., one or more of akathisia, akinesia, restlessness, acute dyskinesia, dystonic reactions, tardive dyskinesia, Parkinson’ s-like symptoms, or neuroleptic malignant syndrome.
  • any foregoing method wherein the lumateperone in free base or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as monotherapy for treatment of Bipolar II Disorder.
  • a mood-stabilizing agent e.g., selected from lithium, carbamazepine, oxcarbazepine, lamotrigine, and valproate (including divalproex (a.k.a. valproate semi sodium), sodium valproate, and other free, salt or complexed forms of valproic acid).
  • a mood-stabilizing agent e.g., selected from lithium, carbamazepine, oxcarbazepine, lamotrigine, and valproate (including divalproex (a.k.a. valproate semi sodium), sodium valproate, and other free, salt or complexed forms of valproic acid).
  • any foregoing method wherein the patient is an adult, e.g., over the age of 18, e.g., between the ages of 18 and 75, inclusive.
  • Method 1.41 wherein said SSRI is selected from citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
  • Method 1.43 wherein said antipsychotic is selected from haloperidol, aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
  • said antipsychotic is selected from haloperidol, aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
  • the disclosure provides lumateperone, in free or
  • the disclosure provides the use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in the manufacture of a medicament for the treatment of Bipolar II Disorder, e.g., for use in any of Methods 1, et seq.
  • treatment and “treating” are to be understood accordingly as embracing prophylaxis and treatment or amelioration of symptoms of disease and/or treatment of the cause of the disease.
  • the words“treatment” and“treating” refer to prophylaxis or amelioration of symptoms of the disease.
  • “Patient” as used herein means a human patient, unless otherwise indicated.
  • Pharmaceutically acceptable salts of lumateperone include pharmaceutically acceptable acid addition salts, for example, toluenesulfonic acid addition salts (tosylate salts).
  • Tosylate salts of lumateperone include the monotosylate salt and the bis-tosylate salt.
  • the term“lumateperone tosylate” refers to the mono-tosylate salt.
  • Lumateperone tosylate is sold as CaplytaTM. Where dosages or amounts of a salt are given by weight, e.g., milligrams per day or milligrams per unit dose, the dosage amount of the salt is given as the weight of the corresponding free base, unless otherwise indicated.
  • the term“concurrently” when referring to a therapeutic use refers to administration of two or more active ingredients to a patient as part of a regimen for the treatment of a disease or disorder, whether the two or more active agents are given at the same or different times or whether given by the same or different routes of administrations. Concurrent administration of the two or more active ingredients may be at different times on the same day, or on different dates or at different frequencies.
  • Lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, may be administered by any suitable route, including oral, parenteral, transdermal, or transmucosal, for example in the form of a tablet, a capsule, a subcutaneous injection, long acting injectable (depot), or an oral, rapidly disintegrating tablet or film for sublingual or buccal administration.
  • lumateperone is provided as a tablet or capsule for oral administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
  • lumateperone is provided as a rapidly disintegrating tablet or film for sublingual or buccal administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
  • lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as a depot formulation, e.g., by dispersing, dissolving, suspending, or encapsulating the compound in a polymeric matrix as described in herein, such that the compound is continually released as the polymer degrades over time.
  • the release of the lumateperone from the polymeric matrix provides for the controlled- and/or delayed- and/or sustained-release, e.g., from the pharmaceutical depot composition, into a subject, for example a warm-blooded animal such as man, to which the pharmaceutical depot is administered.
  • the pharmaceutical depot delivers lumateperone to the subject at
  • Depot composition of the Invention may include a polyester of a hydroxyfatty acid and derivatives thereof or other agents such as polylactic acid, polyglycolic acid, polycitric acid, polymalic acid, poly-beta. -hydroxybutyric acid, epsilon. -capro-lactone ring opening polymer, lactic acid-glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, polylactic acid-polyethylene glycol copolymer or polyglycolic acid-polyethylene glycol copolymer), a polymer of an alkyl alpha-cyanoacrylate (for example poly(butyl 2-cyanoacrylate)), a
  • polyalkylene oxalate for example polytrimethylene oxalate or polytetramethylene oxalate
  • a polyortho ester for example polyethylene carbonate or polyethylene propylene carbonate
  • a polycarbonate for example polyethylene carbonate or polyethylene propylene carbonate
  • a poly ortho-carbonate for example poly-gamma. -L-alanine, poly- .gamma.-benzyl-L-glutamic acid or poly-y-methyl-L-glutamic acid
  • a hyaluronic acid ester and the like, and one or more of these polymers can be used.
  • the polymers are copolymers, they may be any of random, block and/or graft copolymers.
  • any one of D-isomers, L- isomers and/or DL-isomers may be used.
  • alpha-hydroxycarboxylic acid polymer preferably lactic acid-glycolic acid polymer
  • its ester preferably lactic acid-glycolic acid polymer
  • poly-alpha-cyanoacrylic acid esters etc.
  • lactic acid-glycolic acid copolymer also referred to as poly(lactide-alpha- glycolide) or poly(lactic-co-glycolic acid), and hereinafter referred to as PLGA
  • PLGA lactic acid-glycolic acid copolymer
  • the polymer useful for the polymeric matrix is PLGA.
  • the term PLGA includes polymers of lactic acid (also referred to as polylactide, poly(lactic acid), or PLA).
  • the polymer is the biodegradable poly(d,l-lactide-co-glycolide) polymer, such as PLGA 50:50, PLGA 85: 15 and PLGA 90: 10
  • the polymeric matrix of the invention is a biocompatible and biodegradable polymeric material.
  • biocompatible is defined as a polymeric material that is not toxic, is not carcinogenic, and does not significantly induce inflammation in body tissues.
  • the matrix material should be biodegradable wherein the polymeric material should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body.
  • the products of the biodegradation should also be biocompatible with the body in that the polymeric matrix is biocompatible with the body.
  • polymeric matrix materials include poly(glycolic acid), poly-D,L-lactic acid, poly-L-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly (acetals), poly(lactic acid- caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and natural polymers including albumin, casein, and waxes, such as, glycerol mono- and distearate, and the like.
  • One suitable polymer for use in the practice of this invention is dl(polylactide-co-glycolide).
  • the molar ratio of lactide to glycolide in such a copolymer be in the range of from about 75:25 to 50:50.
  • Useful PLGA polymers may have a weight-average molecular weight of from about 5,000 to 500,000 Daltons, preferably about 150,000 Daltons. Dependent on the rate of degradation to be achieved, different molecular weight of polymers may be used. For a diffusional mechanism of drug release, the polymer should remain intact until all of the drug is released from the polymeric matrix and then degrade. The drug can also be released from the polymeric matrix as the polymeric excipient bioerodes.
  • the PLGA may be prepared by any conventional method, or may be commercially available.
  • PLGA can be produced by ring-opening polymerization with a suitable catalyst from cyclic lactide, glycolide, etc. (see EP-0058481B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure).
  • PLGA is biodegradable by means of the degradation of the entire solid polymer composition, due to the break-down of hydrolysable and enzymatically cleavable ester linkages under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid.
  • Both lactic acid and glycolic acid are water-soluble, non-toxic products of normal metabolism, which may further biodegrade to form carbon dioxide and water.
  • PLGA is believed to degrade by means of hydrolysis of its ester groups in the presence of water, for example in the body of a warm-blooded animal such as man, to produce lactic acid and glycolic acid and create the acidic microclimate. Lactic and glycolic acid are by-products of various metabolic pathways in the body of a warm-blooded animal such as man under normal physiological conditions and therefore are well tolerated and produce minimal systemic toxicity.
  • any disclosure of a numerical range, e.g.,“up to X” amount is intended to include the upper numerical limit X. Therefore, a disclosure of“up to 60 mg” is intended to include 60 mg.
  • All references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
  • a multi-center, multi-national, randomized, double-blind, fixed-dose, placebo-controlled clinical trial is conducted substantially in accordance with the following protocol.
  • a total of 381 patients recruited in accordance with the above criteria are randomized 1 : 1 to two study arms: (i) lumateperone 42 mg (administered orally as 60 mg of lumateperone tosylate) and (ii) placebo.
  • lumateperone administered once daily every evening for 6 weeks.
  • placebo is administered once daily every evening for 6 weeks.
  • the total study duration is about 10 weeks, including up to 2 weeks screening period (washout of prohibited medications), a 6-week double-blind treatment period, and 2-week safety follow-up period.
  • the primary outcome measure is the Montgomery -Asberg Depression Rating Scale (MADRS) [Time Frame: Day 43] Secondary outcome measures are the Clinical Global Impression Scale, Bipolar version (CGI-BP) [Time Frame: Day 43] and the Quality of Life Achievement and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) [Time Frame: Day 43] [0047]
  • a further objective of the study is to determine the safety and tolerability of lumateperone versus placebo as measured by:
  • AEs Incidence of Adverse Events
  • YMRS Young Mania Rating Scale
  • C-SSRS Columbia Suicide Severity Rating Scale
  • AIMS Abnormal Involuntary Movement Scale
  • SAS Simpson Angus Scale
  • ECGs Electrocardiograms
  • the patient disposition is as follows:
  • Lumateperone 42 mg was thus superior to placebo as demonstrated by statistically significant improvements on MADRS Total Score and CGI-BP-S which were the primary and key secondary measures in this study. The improvements seen in this study with Lumateperone 42 mg are considered to be clinically meaningful.
  • TEAEs treatment- emergent adverse events
  • Lumateperone 42 mg was generally safe and well tolerated. The most commonly reportec adverse events that were observed at a rate greater than 5% and higher than placebo were headache, somnolence and nausea. Importantly, the rates of akathisia and extrapy rami dal symptoms were less than 1% and similar to placebo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Description

NOVEL METHODS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to and the benefit of U.S. provisional application No. 62/871,170, filed on July 7, 2019, the contents of which are hereby incorporated by reference in its entirety.
TECHNICAL FIELD
[0001] The present disclosure relates to use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, for the treatment of Bipolar II Disorder.
BACKGROUND
[0002] Substituted heterocycle fused gamma-carbolines such as lumateperone are known to be 5-HT2A or 5-HT2A/D2 receptor ligands, which are useful in treating central nervous system disorders. These compounds antagonize the serotonin-2A (5-HT2A) receptor, and/or modulate dopamine receptor signaling at the level of key intra-cellular phosphoproteins. Such compounds are principally known to be useful for the treatment of positive and negative symptoms of schizophrenia. At dopamine D2 receptors, these compounds have dual properties and act as both post-synaptic antagonists and pre-synaptic partial agonists. They also stimulate phosphorylation of glutamatergic NMDA NR2B, or GluN2B, receptors in a mesolimbic specific manner. It is believed that this regional selectivity in the brain areas thought to mediate the efficacy of antipsychotic drugs, together with the serotonergic, glutamatergic, and dopaminergic interactions, may result in antipsychotic efficacy for positive, negative, affective and cognitive symptoms associated with schizophrenia. The compounds also exhibit serotonin reuptake inhibition, providing antidepressant activity for the treatment of schizoaffective disorder, co- morbid depression, and/or as a stand-alone treatment for major depressive disorder. The 5-HT2A or 5-HT2A/D2 receptor ligands as described are also useful for the treatment of bipolar disorder and other psychiatric and neurodegenerative disorders, particularly behavioral disturbances associated with dementia, autism and other CNS diseases. These features may be able to improve the quality of life of patients with schizophrenia and enhance social function to allow them to more fully integrate into their families and their workplace. These compounds display differential dose-dependent effects, selectively targeting the 5-HT2A receptor at low doses, while progressively interacting with the D2 receptor at higher doses. As a result, at lower doses, they are useful in treating sleep, aggression and agitation. At a high-dose, they can treat acute exacerbated and residual schizophrenia, bipolar disorders, and mood disorders.
[0003] Lumateperone, which is 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-lH- pyrido[3',4': 4,5]pyrrolo[l,2,3-de]quinoxalin-8(7H)-yl)-l-(4-fluorophenyl)-l-butanone, having the formula:
Figure imgf000003_0001
is a therapeutic agent now in clinical trials. Lumateperone provides selective and simultaneous modulation of serotonin, dopamine and glutamate neurotransmission. It exhibits potent (Ki=0.5nM) 5-HT2A receptor antagonism, activity as a mesolimbic/mesocortical-selective dopamine receptor protein phosphorylation modulator consistent with presynaptic D2 receptor partial agonism and postsynaptic D2 receptor antagonism (Ki=32nM) in vivo , high D1 receptor affinity (Ki=52nM), and inhibition of the serotonin transporter (SERT) (Ki=26-62nM, using different assays for SERT activity). Lumateperone was approved by the U.S. Food & Drug Administration for the treatment of schizophrenia in 2019, and it is or has been in Phase III clinical development as a treatment for bipolar depression and agitation in dementia, including Alzheimer’s Disease.
[0004] Lumateperone and related compounds have been disclosed in U.S. Pat. No.
Figure imgf000003_0002
compounds useful for the treatment of disorders associated with 5-HT2A receptor modulation such as anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, and social phobias. PCT/US08/03340 and U.S. Pat. No. 7,081,455 also disclose methods of making substituted heterocycle fused gamma- carbolines and uses of these gamma-carbolines as serotonin agonists and antagonists useful for the control and prevention of central nervous system disorders such as addictive behavior and sleep disorders. WO 2009/145900 and U.S. 8,598,119, and WO 2013/155506 and US
2015/0080404, each incorporated herein by reference, disclose the use of specific substituted heterocycle fused gamma-carbolines for the treatment of a combination of psychosis and depressive disorders as well as sleep, depressive and/or mood disorders in patients with psychosis or Parkinson's disease and for the treatment or prophylaxis of disorders associated with dementia, particularly behavioral or mood disturbances such as agitation, irritation,
aggressive/assaultive behavior, anger, physical or emotional outbursts and psychosis and sleep disorders associated with dementia. WO 2009/114181 and U.S. 8,648,077, and
US2020/0157100, each incorporated herein by reference, disclose methods of preparing toluenesulfonic acid addition salt crystals of particular substituted heterocycle fused gamma- carbolines, e.g., toluenesulfonic acid addition salt of lumateperone (mono-tosylate and bis- tosylate salts).
[0005] WO 2011/133224 and U.S. 8,993,572, each incorporated herein by reference, disclose prodrugs/metabolites of substituted heterocycle fused gamma-carbolines for improved formulation, e.g., extended/controlled release formulation. This application discloses that heterocycle fused gamma-carboline N-substituted with a 4-fluorophenyl(4-hydroxy)butyl moiety are shown to have high selectivity for the serotonin transporter (SERT) relative to the
heterocycle fused gamma-carboline containing 4-fluorophenylbutanone.
[0006] WO 2009/145900 (and U.S. 8,598,119) teaches that selected substituted heterocycle fused gamma-carboline compounds have nanomolar affinity for the serotonin reuptake transporter (SERT) and so are selective serotonin reuptake inhibitors.
[0007] As disclosed in WO2015/154025, US 2017/0183350, WO 2017/165843, and US 2019/231780, each incorporated herein by reference, deuterated forms of lumateperone and related compounds have been shown to have improved metabolic stability.
[0008] According to the National Institute of Mental Health, bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. There are four basic types of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely“up,” elated, and energized behavior (known as manic episodes) to very sad,“down,” or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
a. Bipolar I Disorder- defined by manic episodes that last at least 7 days, or by manic
symptoms that are so severe that the person needs immediate hospital care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks. Episodes of depression with mixed features (having depression and manic symptoms at the same time) are also possible.
b. Bipolar II Disorder- defined by a pattern of depressive episodes and hypomanic episodes, but not the full-blown manic episodes described above.
c. Cyclothymic Disorder (also called cyclothymia)- defined by numerous periods of
hypomanic symptoms as well numerous periods of depressive symptoms lasting for at least 2 years (1 year in children and adolescents). However, the symptoms do not meet the diagnostic requirements for a hypomanic episode and a depressive episode.
d. Other Specified and Unspecified Bipolar and Related Disorders- defined by bipolar
disorder symptoms that do not match the three categories listed above.
[0009] The etiology of bipolar disorder remains unclear, and the disorder remains resistant to treatment. Pharmaceutical treatments include mood stabilizing drugs, such as lithium or anticonvulsants (e.g., carbamazepine, lamotrigine, and valproate). Conventional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) are not only less effective for treating bipolar depression than for major depressive disorder, but they may do harm, by triggering manic episodes and rapid cycling.
[0010] Antipsychotic medications are generally effective for short-term treatment of bipolar manic episodes in Bipolar I Disorder, but they are generally ineffective in treating Bipolar II Disorder and in maintenance treatment during depressive episodes. Moreover, many
antipsychotic medications exhibit significant side effects, such as extrapy rami dal symptoms including acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome.
[0011] For example, the atypical antipsychotic aripiprazole was extensively evaluated for treatment of bipolar disorder, but a review of the clinical data concluded:“Although aripiprazole has proven efficacy for acute mania and the prevention of mania, the evidence available thus far does not support the efficacy of aripiprazole for the treatment of acute bipolar depression and prevention of depressive relapse.” Yatham LN,“A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.” J Affect. Disord. 2011 Jan; 128 Suppl ES21-8. Aripiprazole is currently approved in the United States for“Acute Treatment of Manic and Mixed Episodes associated with Bipolar I.” It is not currently approved to treat Bipolar II Disorder.
[0012] While there are many antipsychotic agents approved to treat mania associated with Bipolar I Disorder, only four antipsychotic agents are currently approved in the United States to treat depression associated with Bipolar I Disorder, and only one antipsychotic agent is currently approved in the United States to treat Bipolar II Disorder, quetiapine (Seroquel®). Quetiapine, however, has been reported to be highly sedating and to cause a number of metabolic side effects such as hyperglycemia, dyslipidemia, and weight gain. It also has been associated with emergence of suicidal thoughts in some patients.
[0013] Estimates vary, but it is believed that approximately 30-60% of patients suffering from bipolar disorders suffer from Bipolar II Disorder. Despite its prevalence, Bipolar II Disorder is often misdiagnosed as either Major Depressive Disorder or Bipolar I Disorder, and improperly treated as a result. There is a need for safer and more effective treatments for Bipolar II Disorder, as well as a need for therapies effective to treat both Bipolar I Disorder and Bipolar II Disorder.
BRIEF SUMMARY
[0014] We have surprisingly found that lumateperone is useful to treat Bipolar II Disorder. Clinical results suggest that lumateperone is at least as effective in this indication as existing antipsychotic agents in treating bipolar disorders, with particularly unexpected efficacy in Bipolar II Disorder, which is often resistant to treatment with antipsychotic agents. Moreover, lumateperone exhibits a favorable safety profile. The clinical trials demonstrate that, unlike many other antipsychotic agents, lumateperone does not increase akathisia, restlessness, or other movement disorders, it does not increase suicidal ideation, and it does not have significant metabolic side effects.
[0015] Accordingly, in a first aspect, the present disclosure provides a method for treating Bipolar II Disorder in a patient in need thereof, comprising administering a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form, to a patient in need thereof.
[0016] Further embodiments will be apparent from the following detailed description and examples.
DETAILED DESCRIPTION
[0017] In a Phase 3 clinical trial evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder, lumateperone 42 mg daily (administered orally as 60 mg of the tosylate salt) met the primary endpoint for
improvement in depression as measured by change from baseline versus placebo on the
Montgomery-Asberg Depression Rating Scale (MADRS) total score (p<0.001; effect size = 0.56), as well as its key secondary endpoint, Clinical Global Impression Scale for Bipolar for Severity of Illness (CGI-BP-S) Total Score (p<0.001; effect size = 0.46).
[0018] Moreover, the patients did not exhibit emergence of mania as measured by the Young Mania Rating Scale (YMRS) and a specific clinical global impression of severity for mania, meaning that the drug was effective in preventing the emergence of mania or hypomania, and did not trigger manic episodes or cause rapid cycling that is often linked to SSRIs in treatment of bipolar disorders.
[0019] Unexpectedly, in view of the generally limited efficacy of antipsychotics in Bipolar II Disorder, a subgroup analysis of patients with Bipolar II disorder showed that lumateperone at 42 mg daily was statistically significant superior versus placebo on the MADRS total score.
[0020] Lumateperone demonstrated a favorable safety profile in this trial, comparable to placebo. Unlike quetiapine, lumateperone did not appear to have any noticeable metabolic effects, such as such as hyperglycemia, dyslipidemia, or weight gain. There were no adverse event reports of suicidal ideation, no suicides, and no discontinuations due to suicidal thoughts. Equally important, there were also no adverse event reports of extrapy rami dal symptoms, such as akathisia, restlessness, or other motor side effects.
[0021] Akathisia has been associated with the use of most antipsychotic and antidepressant drugs, particularly in bipolar disorders. Akathisia has been linked to suicide. This highlights the clinical importance of lumateperone, as it can treat Bipolar II Disorder without causing akathisia and is therefore less likely to cause suicidal behaviors. [0022] In a first aspect, the present disclosure provides a method (Method 1) for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form. In further embodiments of the first aspect, the present disclosure provides:
1.1. Method 1, wherein the lumateperone is in the form of the tosylate salt (e.g., an acid addition salt of toluenesulfonic acid, such as a mono-tosylate salt or bis-tosylate salt), optionally wherein the salt is a solid crystalline salt, such as those disclosed in US 2011/112105 and/or US 2020/0157100, the contents of each of which are incorporated by reference herein in their entireties.
1.2. Method 1, wherein lumateperone is in the form of the free base.
1.3. Any foregoing method wherein the lumateperone is in deuterated form, e.g., wherein the deuterium: protium ratio for a specified carbon-bound hydrogen atom is significantly higher, e.g., at least 2x, for example at least lOx higher, than the natural isotope ratios.
1.4. Method 1.3 wherein the lumateperone is in deuterated form selected from:
Figure imgf000008_0001
wherein D represents a hydrogen position with substantially greater than natural deuterium incorporation (i.e., substantially greater than 0.0156%), e.g., greater than 60%, or greater than 70%, or greater than 80%, or greater than 90% or greater than 95%, or greater than 96%, or greater than 97%, or greater than 98%, or greater than 99%, in free or pharmaceutically acceptable salt form, e.g. tosylate salt form.
Any foregoing method, wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 6 to 60 mg of free base, e.g., equivalent to 20-50 mg of free base.
Any foregoing method, wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 25-30 mg of free base.
Any foregoing method, wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 40-45mg of free base.
Any foregoing method, wherein the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 42 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
Any foregoing method, wherein the method comprises once daily administration of a tablet or capsule comprising about 60 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
. Any foregoing method, wherein the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 28 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
. Any foregoing method, wherein the method comprises once daily administration of a tablet or capsule comprising about 40 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.. Any foregoing method, wherein the method comprises once daily administration of a unit dosage for subcutaneous or transmucosal administration, e.g., a sublingual or buccal orally disintegrating tablet or film, comprising lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, in an amount equivalent to 10-60 mg of free base, and a pharmaceutically acceptable diluent or carrier.
. Any foregoing method wherein the method comprises administration of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in a long acting injectable form.
. Any foregoing method wherein the patient has been diagnosed with Bipolar II Disorder.. Any foregoing method wherein the condition to be treated is depression in Bipolar II Disorder, or a depressive episode associated with Bipolar II Disorder (e.g., a major depressive episode).
. Any foregoing method wherein the condition to be treated includes mixed affective episodes in Bipolar II Disorder.
. Any foregoing method wherein the condition to be treated includes hypomanic episodes.. Any foregoing method wherein the treatment suppresses mania or hypomania.
. Any foregoing method wherein the treatment does not trigger manic or hypomanic episodes or rapid cycling.
. Any foregoing method wherein, during the course of treatment, the patient does not exhibit emergence of mania or hypomania as measured by the Young Mania Rating Scale (YMRS).
. Any foregoing method wherein, during the course of treatment, the patient shows improvement in depressive symptoms, e.g., as measured using one or more of the
Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Rating Scale (HAM-D), the Beck Depression Inventory (BDI), the Zung Self-Rating Depression Scale, the Wechsler Depression Rating Scale, the Raskin Depression Rating Scale, the Inventory of Depressive Symptomatology (IDS), or the Quick Inventory of Depressive Symptomatology (QIDS)
. Any foregoing method wherein, during the course of treatment, the patient shows improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score (e.g., improvement within 8 days or less after initiation of treatment).
. Any foregoing method wherein, following treatment, the patient shows improvement in Clinical Global Impression Scale for Bipolar for Severity of Illness (CGI-BP-S) (e.g., improvement within 8 days or less after initiation of treatment). . Any foregoing method wherein, during the course of treatment, the patient shows improvement in Clinical Global Impression Scale for Bipolar Depression for Severity of Illness (CGI- BP- Depression-S) (e.g., improvement within 8 days or less after initiation of treatment).
. Any foregoing method wherein, during the course of treatment, the patient does not show an increase in Clinical Global Impression Scale for Bipolar Mania for Severity of Illness
(C GI-BP-Mani a- S) .
. Any foregoing method wherein, during the course of treatment, the patient shows improvement in overall mental health, e.g., as measured using Clinical Global Impression - Severity (CGI-S) or Clinical Global Impression- Improvement (CGI-I) (e.g., improvement within 8 days or less after initiation of treatment).
. Any foregoing method wherein the treatment does not result in metabolic side effects, e.g., does not result in one or more of hyperglycemia, dyslipidemia, or weight gain.
. Any foregoing method wherein the treatment does not induce suicidal ideation or suicidal thoughts.
. Any foregoing method wherein the treatment does not induce extrapy rami dal symptoms, e.g., one or more of akathisia, akinesia, restlessness, acute dyskinesia, dystonic reactions, tardive dyskinesia, Parkinson’ s-like symptoms, or neuroleptic malignant syndrome.
. Any foregoing method wherein the treatment does not induce akathisia.
. Any foregoing method wherein the lumateperone in free base or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as monotherapy for treatment of Bipolar II Disorder.
. Any foregoing method wherein the patient is concurrently receiving a mood-stabilizing agent, e.g., selected from lithium, carbamazepine, oxcarbazepine, lamotrigine, and valproate (including divalproex (a.k.a. valproate semi sodium), sodium valproate, and other free, salt or complexed forms of valproic acid).
. Any foregoing method wherein the patient is concurrently receiving lithium or valproate.. Any foregoing method wherein the patient is under the age of 18.
. Any foregoing method wherein the patient is an adult, e.g., over the age of 18, e.g., between the ages of 18 and 75, inclusive.
. Any foregoing method wherein the patient is elderly, e.g., 65 or older, e.g. 75 or older. 1.37. Any foregoing method wherein the lumateperone in free or salt form is indicated for use in the treatment of depression in Bipolar I Disorder and Bipolar II Disorder.
1.38. Any foregoing method wherein the duration of treatment is six weeks or less.
1.39. Any foregoing method wherein the treatment is a maintenance treatment.
1.40. Any foregoing method wherein the duration of treatment is six weeks or more.
1.41. Any foregoing method, wherein the patient was previously treated with an SSRI (e.g., such treatment was ineffective and/or discontinued, such as due to side effects).
1.42. Method 1.41, wherein said SSRI is selected from citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
1.43. Any foregoing method, wherein the patient was previously treated with an antipsychotic, such as an atypical antipsychotic (e.g., such treatment was ineffective and/or discontinued, such as due to side effects).
1.44. Method 1.43, wherein said antipsychotic is selected from haloperidol, aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
[0023] In another aspect, the disclosure provides lumateperone, in free or
pharmaceutically acceptable salt form, optionally in deuterated form, for use in the treatment of Bipolar II Disorder, e.g., for use in any of Methods 1, et seq.
[0024] In another aspect, the disclosure provides the use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in the manufacture of a medicament for the treatment of Bipolar II Disorder, e.g., for use in any of Methods 1, et seq.
[0025] The words "treatment" and "treating" are to be understood accordingly as embracing prophylaxis and treatment or amelioration of symptoms of disease and/or treatment of the cause of the disease. In particular embodiments, the words“treatment” and“treating” refer to prophylaxis or amelioration of symptoms of the disease.
[0026]“Patient” as used herein means a human patient, unless otherwise indicated.
[0027] Pharmaceutically acceptable salts of lumateperone include pharmaceutically acceptable acid addition salts, for example, toluenesulfonic acid addition salts (tosylate salts). Tosylate salts of lumateperone include the monotosylate salt and the bis-tosylate salt. Unless otherwise indicated, the term“lumateperone tosylate” refers to the mono-tosylate salt. Lumateperone tosylate is sold as Caplyta™. Where dosages or amounts of a salt are given by weight, e.g., milligrams per day or milligrams per unit dose, the dosage amount of the salt is given as the weight of the corresponding free base, unless otherwise indicated.
[0028] The term“concurrently” when referring to a therapeutic use refers to administration of two or more active ingredients to a patient as part of a regimen for the treatment of a disease or disorder, whether the two or more active agents are given at the same or different times or whether given by the same or different routes of administrations. Concurrent administration of the two or more active ingredients may be at different times on the same day, or on different dates or at different frequencies.
[0029] Dosages employed in practicing the present disclosure will of course vary depending, e.g. on the particular disease or condition to be treated, the particular active compounds used, the mode of administration, and the therapy desired. Lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, may be administered by any suitable route, including oral, parenteral, transdermal, or transmucosal, for example in the form of a tablet, a capsule, a subcutaneous injection, long acting injectable (depot), or an oral, rapidly disintegrating tablet or film for sublingual or buccal administration.
[0030] In some embodiments, lumateperone is provided as a tablet or capsule for oral administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
[0031] In some embodiments, lumateperone is provided as a rapidly disintegrating tablet or film for sublingual or buccal administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
[0032] In some embodiments, lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as a depot formulation, e.g., by dispersing, dissolving, suspending, or encapsulating the compound in a polymeric matrix as described in herein, such that the compound is continually released as the polymer degrades over time. The release of the lumateperone from the polymeric matrix provides for the controlled- and/or delayed- and/or sustained-release, e.g., from the pharmaceutical depot composition, into a subject, for example a warm-blooded animal such as man, to which the pharmaceutical depot is administered. Thus, the pharmaceutical depot delivers lumateperone to the subject at
concentrations effective for treatment of the particular disease or medical condition over a sustained period of time, e.g., 1 week to 3 months. [0033] Polymers useful for the polymeric matrix in the Composition of the Invention (e.g.,
Depot composition of the Invention) may include a polyester of a hydroxyfatty acid and derivatives thereof or other agents such as polylactic acid, polyglycolic acid, polycitric acid, polymalic acid, poly-beta. -hydroxybutyric acid, epsilon. -capro-lactone ring opening polymer, lactic acid-glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, polylactic acid-polyethylene glycol copolymer or polyglycolic acid-polyethylene glycol copolymer), a polymer of an alkyl alpha-cyanoacrylate (for example poly(butyl 2-cyanoacrylate)), a
polyalkylene oxalate (for example polytrimethylene oxalate or polytetramethylene oxalate), a polyortho ester, a polycarbonate (for example polyethylene carbonate or polyethylene propylene carbonate), a poly ortho-carbonate, a polyamino acid (for example poly-gamma. -L-alanine, poly- .gamma.-benzyl-L-glutamic acid or poly-y-methyl-L-glutamic acid), a hyaluronic acid ester, and the like, and one or more of these polymers can be used.
[0034] If the polymers are copolymers, they may be any of random, block and/or graft copolymers. When the above alpha-hydroxycarboxylic acids, hydroxydicarboxylic acids and hydroxytricarboxylic acids have optical activity in their molecules, any one of D-isomers, L- isomers and/or DL-isomers may be used. Among others, alpha-hydroxycarboxylic acid polymer (preferably lactic acid-glycolic acid polymer), its ester, poly-alpha-cyanoacrylic acid esters, etc. may be used, and lactic acid-glycolic acid copolymer (also referred to as poly(lactide-alpha- glycolide) or poly(lactic-co-glycolic acid), and hereinafter referred to as PLGA) are preferred. Thus, in one aspect the polymer useful for the polymeric matrix is PLGA. As used herein, the term PLGA includes polymers of lactic acid (also referred to as polylactide, poly(lactic acid), or PLA). Most preferably, the polymer is the biodegradable poly(d,l-lactide-co-glycolide) polymer, such as PLGA 50:50, PLGA 85: 15 and PLGA 90: 10
[0035] In one such embodiment, the polymeric matrix of the invention is a biocompatible and biodegradable polymeric material. The term“biocompatible” is defined as a polymeric material that is not toxic, is not carcinogenic, and does not significantly induce inflammation in body tissues. The matrix material should be biodegradable wherein the polymeric material should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body. The products of the biodegradation should also be biocompatible with the body in that the polymeric matrix is biocompatible with the body. Particular useful examples of polymeric matrix materials include poly(glycolic acid), poly-D,L-lactic acid, poly-L-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly (acetals), poly(lactic acid- caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and natural polymers including albumin, casein, and waxes, such as, glycerol mono- and distearate, and the like. One suitable polymer for use in the practice of this invention is dl(polylactide-co-glycolide). In one embodiment, the molar ratio of lactide to glycolide in such a copolymer be in the range of from about 75:25 to 50:50.
[0036] Useful PLGA polymers may have a weight-average molecular weight of from about 5,000 to 500,000 Daltons, preferably about 150,000 Daltons. Dependent on the rate of degradation to be achieved, different molecular weight of polymers may be used. For a diffusional mechanism of drug release, the polymer should remain intact until all of the drug is released from the polymeric matrix and then degrade. The drug can also be released from the polymeric matrix as the polymeric excipient bioerodes.
[0037] The PLGA may be prepared by any conventional method, or may be commercially available. For example, PLGA can be produced by ring-opening polymerization with a suitable catalyst from cyclic lactide, glycolide, etc. (see EP-0058481B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure).
[0038] It is believed that PLGA is biodegradable by means of the degradation of the entire solid polymer composition, due to the break-down of hydrolysable and enzymatically cleavable ester linkages under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid. Both lactic acid and glycolic acid are water-soluble, non-toxic products of normal metabolism, which may further biodegrade to form carbon dioxide and water. In other words, PLGA is believed to degrade by means of hydrolysis of its ester groups in the presence of water, for example in the body of a warm-blooded animal such as man, to produce lactic acid and glycolic acid and create the acidic microclimate. Lactic and glycolic acid are by-products of various metabolic pathways in the body of a warm-blooded animal such as man under normal physiological conditions and therefore are well tolerated and produce minimal systemic toxicity.
[0039] For the avoidance of doubt, any disclosure of a numerical range, e.g.,“up to X” amount is intended to include the upper numerical limit X. Therefore, a disclosure of“up to 60 mg” is intended to include 60 mg. [0040] All references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
[0041] The disclosure is further illustrated in the following examples, which are meant to be exemplary and not limiting.
Example 1: Clinical Trial in Bipolar Disorder patients
Figure imgf000016_0001
[0042] A multi-center, multi-national, randomized, double-blind, fixed-dose, placebo-controlled clinical trial is conducted substantially in accordance with the following protocol.
[0043] Patients are recruited according to the following criteria:
- Major Inclusion Criteria: Male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder, experiencing a current major depressive episode, and able to provide written informed consent.
- Major Exclusion Criteria: Any female subject who is pregnant or breast-feeding, and any subject judged to be medically inappropriate for study participation.
[0044] A total of 381 patients recruited in accordance with the above criteria are randomized 1 : 1 to two study arms: (i) lumateperone 42 mg (administered orally as 60 mg of lumateperone tosylate) and (ii) placebo. In the lumateperone arm, lumateperone (lumateperone tosylate 60 mg) is administered once daily every evening for 6 weeks. In the placebo arm, placebo is
administered once daily every evening for 6 weeks. The patients do not receive other
medications for treatment of bipolar disorders. The study is quadruple-masked (i.e., to participant, care provider, investigator, and outcomes assessor).
[0045] The total study duration is about 10 weeks, including up to 2 weeks screening period (washout of prohibited medications), a 6-week double-blind treatment period, and 2-week safety follow-up period.
[0046] The primary outcome measure is the Montgomery -Asberg Depression Rating Scale (MADRS) [Time Frame: Day 43] Secondary outcome measures are the Clinical Global Impression Scale, Bipolar version (CGI-BP) [Time Frame: Day 43] and the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) [Time Frame: Day 43] [0047] A further objective of the study is to determine the safety and tolerability of lumateperone versus placebo as measured by:
a. Incidence of Adverse Events (AEs) b. Young Mania Rating Scale (YMRS)
c. Columbia Suicide Severity Rating Scale (C-SSRS)
d. Abnormal Involuntary Movement Scale (AIMS)
e. Barnes Akathisia Rating Scale (BARS)
f. Simpson Angus Scale (SAS)
g. Clinical laboratory evaluations
h. Electrocardiograms (ECGs)
i. Vital sign measurements
j. Physical examination and neurological findings
[0048] The patient disposition is as follows:
Table 1
Figure imgf000017_0001
0049] The change seen from baseline to Day 43 in MADRS total score was as follows:
Table 2
Figure imgf000017_0002
0050] The change seen from baseline to Day 43 in CGI-BP-S total score was as follows: Table 3
Figure imgf000018_0002
0051] Lumateperone 42 mg was thus superior to placebo as demonstrated by statistically significant improvements on MADRS Total Score and CGI-BP-S which were the primary and key secondary measures in this study. The improvements seen in this study with Lumateperone 42 mg are considered to be clinically meaningful.
[0052] The safety profile of lumateperone was similar to placebo. A summary of treatment- emergent adverse events (TEAEs) is as follows:
Table 4
Figure imgf000018_0001
Figure imgf000019_0001
0053] Lumateperone 42 mg was generally safe and well tolerated. The most commonly reportec adverse events that were observed at a rate greater than 5% and higher than placebo were headache, somnolence and nausea. Importantly, the rates of akathisia and extrapy rami dal symptoms were less than 1% and similar to placebo.
[0054] In this trial, once-daily lumateperone 42 mg met the primary endpoint with statistically significant greater improvement over placebo at week 6 (trial endpoint), as measured by change from baseline on the MADRS total score. In the intent-to-treat (ITT) study population, the least squares (LS) mean reduction from baseline for lumateperone 42 mg was 16.7 points, versus 12.1 points for placebo (LS mean difference = 4.6 points; effect size = 0.56, p<0.001). Moreover, lumateperone 42 mg showed statistically significant separation from placebo as early as week 1, which was maintained at every time point throughout the entire trial.
[0055] Lumateperone 42 mg also met the key secondary endpoint of statistically significant improvement on the CGI-BP-S Total Score (p<0.001; effect size = 0.46) and on the CGI component that specifically assesses depression (CGI- S Depression Score; p<0.001; effect size = 0.5).
[0056] These results were supported by statistically significant benefits on responder rates and remission rates, demonstrating the clinical meaningfulness of the primary outcome. In addition, in a subgroup analysis of patients with Bipolar II disorder lumateperone 42 mg was statistically significant superior to placebo on the MADRS total score.

Claims

CLAIMS We claim:
1. A method for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or
pharmaceutically acceptable salt form, optionally in deuterated form.
2. The method of claim 1, wherein the lumateperone is in the form of a toluenesulfonic acid addition salt (e.g., a mono-tosylate salt or bis-tosylate salt).
3. The method of claim 2, wherein the salt is a solid crystalline salt.
4. The method of any one of claims 1-3, wherein the lumateperone is in deuterated form.
5. The method of any one of claims 1-4, wherein the lumateperone, in free or
pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 6 to 60 mg of free base.
6. The method of any foregoing claim, wherein the method comprises once daily
administration of a tablet or capsule comprising about 60 mg of lumateperone tosylate in combination or association with a pharmaceutically acceptable diluent or carrier.
7. The method of any foregoing claim, wherein the condition to be treated is depression in Bipolar II Disorder, or a depressive episode associated with Bipolar II Disorder (e.g., a major depressive episode).
8. The method of any foregoing claim, wherein during the course of treatment the patient shows improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score and/or shows improvement in Clinical Global Impression Scale for Bipolar for Severity of Illness (CGI-BP-S) (e.g., improvement within 8 days or less after initiation of treatment).
9. The method of any foregoing claim, wherein the treatment does not result in one or more of hyperglycemia, dyslipidemia, weight gain, suicidal ideation or suicidal thoughts, or extrapy rami dal symptoms including akathisia.
10. The method of any foregoing claim, wherein the patient is concurrently receiving a
mood-stabilizing agent.
11. The method of any foregoing claim, wherein the patient was previously treated with an SSRI (e.g., such treatment was ineffective and/or discontinued, such as due to side effects).
12. The method of any foregoing claim, wherein the patient was previously treated with an antipsychotic, such as an atypical antipsychotic (e.g., such treatment was ineffective and/or discontinued, such as due to side effects).
13. The method of claim 12, wherein said antipsychotic is selected from haloperidol,
aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
14. Lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, for use in the method of any of the foregoing claims.
PCT/US2020/041063 2019-07-07 2020-07-07 Novel methods Ceased WO2021007245A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2022000143A MX2022000143A (en) 2019-07-07 2020-07-07 NOVELTY METHODS.
EP22191949.1A EP4134101A1 (en) 2019-07-07 2020-07-07 Deuterated lumateperone for the treatment of the bipolar ii disorder
AU2020311894A AU2020311894B2 (en) 2019-07-07 2020-07-07 Novel methods
CA3141223A CA3141223A1 (en) 2019-07-07 2020-07-07 Novel methods
JP2022500683A JP7673040B2 (en) 2019-07-07 2020-07-07 New Method
CN202080049820.3A CN114072150A (en) 2019-07-07 2020-07-07 New method
BR112022000231A BR112022000231A2 (en) 2019-07-07 2020-07-07 new methods
KR1020227003969A KR20220029744A (en) 2019-07-07 2020-07-07 new method
EP20837066.8A EP3993798A4 (en) 2019-07-07 2020-07-07 NEW PROCESSES
IL289589A IL289589A (en) 2019-07-07 2022-01-03 Novel methods
MX2025005489A MX2025005489A (en) 2019-07-07 2022-01-03 Novel methods
JP2025071306A JP2025121928A (en) 2019-07-07 2025-04-23 New Method
AU2025234205A AU2025234205A1 (en) 2019-07-07 2025-09-18 Novel methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871170P 2019-07-07 2019-07-07
US62/871,170 2019-07-07

Publications (1)

Publication Number Publication Date
WO2021007245A1 true WO2021007245A1 (en) 2021-01-14

Family

ID=74066254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/041063 Ceased WO2021007245A1 (en) 2019-07-07 2020-07-07 Novel methods

Country Status (11)

Country Link
US (3) US20210000822A1 (en)
EP (2) EP3993798A4 (en)
JP (2) JP7673040B2 (en)
KR (1) KR20220029744A (en)
CN (1) CN114072150A (en)
AU (2) AU2020311894B2 (en)
BR (1) BR112022000231A2 (en)
CA (1) CA3141223A1 (en)
IL (1) IL289589A (en)
MX (2) MX2022000143A (en)
WO (1) WO2021007245A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral preparations of heterocyclic gamma carboline derivatives fused for absorption through mucous membranes
CN111107847A (en) 2017-09-26 2020-05-05 细胞内治疗公司 Novel salts and crystals
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112584837A (en) 2018-08-31 2021-03-30 细胞内治疗公司 New method
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. Novel methods
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
WO2022051770A2 (en) * 2020-09-04 2022-03-10 Intra-Cellular Therapies, Inc. Novel salts, crystals, and co-crystals
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
AU2023320312A1 (en) * 2022-07-30 2025-01-16 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN115671057A (en) * 2022-10-19 2023-02-03 四川迈可隆生物科技有限公司 Rumepilone pharmaceutical composition, long-acting microsphere sustained-release preparation and preparation method thereof
CN115554237B (en) * 2022-12-08 2023-09-12 山东则正医药技术有限公司 Rumex-pirone in-situ gel long-acting injection and preparation method and application thereof
EP4678165A1 (en) * 2023-03-03 2026-01-14 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Long-acting and sustained-release preparation composition of lumateperone and preparation method therefor

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548493B1 (en) 1999-06-15 2003-04-15 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
WO2009114181A2 (en) 2008-03-12 2009-09-17 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
US9745300B2 (en) * 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2017165843A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2018031535A1 (en) * 2016-08-09 2018-02-15 Assia Chemical Industries Ltd. Solid state forms of lumateperone ditosylate salt
US20200157100A1 (en) 2018-06-06 2020-05-21 Intra-Cellular Therapies, Inc. Novel salts and crystals

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (en) 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
ATE59289T1 (en) 1985-10-09 1991-01-15 Desitin Arzneimittel Gmbh PROCESS FOR PREPARING A PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL INGREDIENTS, REAGENTS OR OTHER INGREDIENTS.
ES2058068T3 (en) 1986-03-19 1994-11-01 Kumiai Chemical Industry Co DERIVATIVES OF 5H-1,3,4-TIADIAZOL- (3,2-A) -PIRIMIDIN-5-ONA AND FUNGICIDE COMPOUNDS CONTAINED IN SUCH DERIVATIVES.
EP0242690B1 (en) 1986-04-07 1993-06-30 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (en) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
JP3016060B2 (en) 1993-04-28 2000-03-06 本田技研工業株式会社 Anti-vibration mounting device
CN1074923C (en) 1993-11-19 2001-11-21 詹森药业有限公司 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP4099224B2 (en) 1994-03-02 2008-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン Sublingual or buccal pharmaceutical composition
CN1087725C (en) 1994-03-25 2002-07-17 同位素技术有限公司 Enhancement of the effect of drugs by deuteration
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
NO309305B1 (en) 1999-02-19 2001-01-15 Norsk Hydro As Use of benzaldehyde derivatives in the manufacture of pharmaceutical preparations for the prevention and / or treatment of cancer, as well as certain new benzaldehyde derivatives
PE20010052A1 (en) 1999-04-23 2001-01-27 Upjohn Co AZEPININDOL TETRACYCLIC COMPOUNDS AS AGONISTS OR ANTAGONISTS OF THE 5-HT RECEPTOR
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
PL366233A1 (en) 2000-12-20 2005-01-24 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
DE10123129A1 (en) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
US6849640B2 (en) 2001-08-08 2005-02-01 Pharmacia & Upjohn Company Therapeutic 1H-pyrido [4,3-b] indoles
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
EP1314554A1 (en) 2001-11-23 2003-05-28 Kba-Giori S.A. Removing device for security-elements
DE10162121A1 (en) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterated substituted pyrazolyl-benzenesulfonamides and drugs containing these compounds
KR100699516B1 (en) 2002-07-29 2007-03-26 알자 코포레이션 Methods and dosage forms for the controlled delivery of paliperidone
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003287433A1 (en) 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
PL377426A1 (en) 2002-12-19 2006-02-06 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
DK2009000T3 (en) 2003-01-16 2011-09-05 Acadia Pharm Inc Selective serotonin 2A / 2C receptor inverse agonists as therapeutics for neurodegenerative diseases
AU2004259741A1 (en) 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
AR045796A1 (en) 2003-09-26 2005-11-16 Solvay Pharm Bv DERIVATIVES OF HEXA AND OCTAHIDRO - PIRIDO (1,2-A) PIRAZINA WITH ANTAGONIST ACTIVITY OF NK1. PHARMACEUTICAL COMPOSITIONS.
JP2005259113A (en) 2004-02-12 2005-09-22 Ricoh Co Ltd Process editing apparatus, process management apparatus, process editing program, process management program, recording medium, process editing method and process management method
US20080280941A1 (en) 2004-03-05 2008-11-13 Pierre Lourtie 8-Phenoxy-Gamma Carboline Derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
AU2005286943A1 (en) 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
JP2008513432A (en) 2004-09-21 2008-05-01 ファイザー・プロダクツ・インク N-methylhydroxyethylamine useful for the treatment of CNS conditions
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
WO2006063709A1 (en) 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
WO2006081332A1 (en) 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
JP2008528514A (en) 2005-01-25 2008-07-31 セルジーン・コーポレーション Methods and compositions using 4-amino-2- (3-methyl-2,6-dioxopiperidin-3-yl) -isoindole-1,3-dione
CN101309917B (en) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 Deuterated inhibitor of gastric H+, K+-ATPase with enhanced therapeutic properties
WO2007084841A2 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102065319B1 (en) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted heterocycle fused gamma-carbolines synthesis
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
AU2009212065B2 (en) 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition
MX2010008688A (en) 2008-02-07 2010-08-30 Schering Corp Engineered anti-tslpr antibodies.
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
SG11201501894VA (en) 2012-09-14 2015-04-29 Abbvie Inc Tricyclic quinoline and quinoxaline derivatives
HUE053159T2 (en) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Organic compounds
IL305990B2 (en) 2013-12-03 2025-12-01 Intra Cellular Therapies Inc A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
JP6537601B2 (en) 2015-05-12 2019-07-03 大鵬薬品工業株式会社 Crystal of azabicyclic compound
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. Dosage forms and use thereof
CN108883111B (en) 2016-01-26 2021-10-08 细胞内治疗公司 organic compounds
US20200392135A1 (en) 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP2019513143A (en) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Novel salts and crystals
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral preparations of heterocyclic gamma carboline derivatives fused for absorption through mucous membranes
JP7224333B2 (en) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド organic compound
JP7223742B2 (en) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド organic compound
US11655251B2 (en) * 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. Novel methods
JP2025521115A (en) 2022-05-18 2025-07-08 イントラ－セルラー・セラピーズ・インコーポレイテッド New Method

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548493B1 (en) 1999-06-15 2003-04-15 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6552017B1 (en) 1999-06-15 2003-04-22 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7081455B2 (en) 1999-06-15 2006-07-25 Bristol-Myers Squibb Company Substituted heterocycle fused gamma-carbolines
USRE39679E1 (en) 1999-06-15 2007-06-05 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
USRE39680E1 (en) 1999-06-15 2007-06-05 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7238690B2 (en) 1999-06-15 2007-07-03 Bristol-Myers Squibb Company Substituted heterocycle fused gamma-carbolines
WO2009114181A2 (en) 2008-03-12 2009-09-17 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
US8648077B2 (en) 2008-03-12 2014-02-11 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
US20110112105A1 (en) 2008-03-12 2011-05-12 John Tomesch Substituted heterocycle fused gamma-carbolines solid
US8598119B2 (en) 2008-05-27 2013-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
US20150080404A1 (en) 2012-04-14 2015-03-19 Intra-Cellular Therapies, Inc. Novel compositions and methods
US20170183350A1 (en) 2014-04-04 2017-06-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US9745300B2 (en) * 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
WO2017165843A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
US20190231780A1 (en) 2016-03-25 2019-08-01 Intra-Cellular Therapies, Inc. Organic compounds
WO2018031535A1 (en) * 2016-08-09 2018-02-15 Assia Chemical Industries Ltd. Solid state forms of lumateperone ditosylate salt
US20200157100A1 (en) 2018-06-06 2020-05-21 Intra-Cellular Therapies, Inc. Novel salts and crystals

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Treatment of Bipolar Depression Conducted Globally", 8 January 2019, NATIONAL INSTITUTE OF HEALTH
KUMAR B. ET AL., DRUGS OF TODAY, vol. 54, no. 12, 1 December 2018 (2018-12-01)
ROBERT E. DAVIS ET AL., EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 16, no. 6, 2 June 2016 (2016-06-02)
See also references of EP3993798A4
U.S. NATIONAL LIBRARY OF MEDICINE: "History of Changes for Study: NCT03249376, Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally", NATIONAL INSTITUTE OF HEALTH, 8 January 2019 (2019-01-08), pages 1 - 4, XP055782711, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03249376?V_5=View#StudyPageTop> [retrieved on 20200922] *
YATHAM LN: "A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder", J. AFFECT. DISORD, vol. 128, no. 1, January 2011 (2011-01-01), pages 21 - 8

Also Published As

Publication number Publication date
EP3993798A1 (en) 2022-05-11
IL289589A (en) 2022-03-01
JP2022539821A (en) 2022-09-13
AU2020311894B2 (en) 2025-06-26
BR112022000231A2 (en) 2022-02-22
EP4134101A1 (en) 2023-02-15
US12090155B2 (en) 2024-09-17
MX2022000143A (en) 2022-02-17
AU2025234205A1 (en) 2025-10-09
AU2020311894A1 (en) 2022-01-27
JP2025121928A (en) 2025-08-20
MX2025005489A (en) 2025-06-02
JP7673040B2 (en) 2025-05-08
US20240374586A1 (en) 2024-11-14
US20210000822A1 (en) 2021-01-07
CA3141223A1 (en) 2021-01-14
EP3993798A4 (en) 2023-04-26
CN114072150A (en) 2022-02-18
KR20220029744A (en) 2022-03-08
US20240066030A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US12090155B2 (en) Methods
US12496300B2 (en) Methods of treating acute depression and anxiety
Stahlmann Clinical toxicological aspects of fluoroquinolones
JP2025093929A (en) Preventive and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, comprising brexpiprazole or a salt thereof
JP7821366B1 (en) New Method
AU2013323133A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington&#39;s disease
EP3645120B1 (en) Nk-1 antagonist compositions and methods for use in treating depression
US20200179351A1 (en) Treatment of depressive disorders
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
AU2018383098A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20080242682A1 (en) Preventive or Therapeutic Agent for Sleep Disorder
HK40087977A (en) Deuterated lumateperone for the treatment of the bipolar ii disorder
HK40066295A (en) Novel methods
US20260115188A1 (en) Methods of treating centeral nervous system disorders comprising administering deuterated lumateperone and a nitric oxide donor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20837066

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3141223

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022500683

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022000231

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020311894

Country of ref document: AU

Date of ref document: 20200707

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227003969

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020837066

Country of ref document: EP

Effective date: 20220207

ENP Entry into the national phase

Ref document number: 112022000231

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220106

WWR Wipo information: refused in national office

Ref document number: 2022102696

Country of ref document: RU

WWG Wipo information: grant in national office

Ref document number: MX/A/2022/000143

Country of ref document: MX